ArticleClinical rheumatology2026
Seizures as a marker of severe multi-organ involvement in neuropsychiatric systemic lupus erythematosus: a diagnostic risk stratification study.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveThis study aimed to identify independent predictors of seizure occurrence in patients with neuropsychiatric systemic lupus erythematosus (NPSLE), develop a diagnostic model, and evaluate whether seizures are associated with adverse renal outcomes.
methodsA retrospective cohort of 169 patients with NPSLE from Xiangya Hospital was analyzed. Among 70 pre-specified clinical, laboratory, and imaging variables, 20 variables associated with seizure occurrence (p < 0.05 in univariable logistic regression) were retained after multicollinearity screening (VIF < 5.0). Multivariable logistic regression was then performed to identify independent predictors of SE-NPSLE. Machine learning algorithms with fivefold cross-validation were then employed to develop and optimize the diagnostic model. Model performance was evaluated using sensitivity, specificity, accuracy, and AUC metrics. External validation was performed using an independent cohort (n = 46) from Jiangsu Provincial People's Hospital. Renal survival rates were assessed by Kaplan-Meier analysis with log-rank tests.
resultsIndependent predictors of SE-NPSLE included anti-Rib-P antibody (OR = 0.315, 95% CI: 0.121-0.819), erythrocyte sedimentation rate (ESR) (OR = 0.973 per mm/h, 95% CI: 0.954-0.992), and presence of psychosis (OR = 0.194, 95% CI: 0.057-0.659). A logistic regression-based nomogram (AUC: 0.818 training, 0.800 validation) demonstrated robust performance. External validation (n = 46) yielded an AUC of 0.706. What is more, NPSLE patients with seizures (SE-NPSLE) demonstrated significantly worse renal outcomes compared to NPSLE patients without seizures (non-SE-NPSLE).
conclusionSeizures in NPSLE are associated with poor renal prognosis. Our diagnostic model was developed to facilitate early risk assessment and may aid personalized seizure management; however, its clinical utility requires validation in larger, prospective cohorts. Key Points • A validated diagnostic model indentifies high-risk NPSLE patients for seizures. • 3 independent predictors of SE-NPSLE included anti-Rib-P antibodies, ESR and psychosis. • SE-NPSLE patients were youner, had higher SLEDAI, and exhibited more severe renal dysfunction than non-SE-NPSLE patients.
Indexed as
Identifiers
42870198What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.